Trial · NCT02769832
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
NCT02769832, Phase 2, Completed, Muhammad Furqan; results first posted 2023-07-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer. Trials, record NCT02769832. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02769832
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
- NCT number
- NCT02769832
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 32 participants, actual
- Lead sponsor
- Muhammad Furqan
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Nab-paclitaxel, Gemcitabine
- First posted
- 2016-05-12
- Last updated
- 2025-07-29
- Results first posted
- 2023-07-21
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years) | Overall response rate is defined as the percentage of patients with a confirmed complete or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT scan: Complete response (CR) is the disappearance of all target lesions. Partial Response (PR), is at least a ≥ 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum of the longest diameter (LD). Progression of disease (PD) is at least a ≥ 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and as defined by RECIST v1.1 guidelines. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD. |
| Secondary | Progression-Free Survival | Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years) | Progression-free survival is defined as the time from treatment initiation to the date of first documentation of disease progression or death due to any cause. Otherwise, patients are censored at the date of last radiographic assessment for progression. |
| Secondary | Time to Progression | Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years) | Time to progression is defined as the time from treatment initiation to the date of first documentation of disease progression per RECIST v1.1. Otherwise, patients are censored at last radiographic assessment for progression. |
| Secondary | Overall Survival | Patients will be evaluated every 3 months until death or study completion (up to 3 years) | Overall survival is defined as the time from treatment initiation to death due to any cause. Patients still alive are censored at last date known to be alive. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression-Free Survival | Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years) | months | MEDIAN | |
| SECONDARY | Time to Progression | Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years) | months | MEDIAN | |
| SECONDARY | Overall Survival | Patients will be evaluated every 3 months until death or study completion (up to 3 years) | months | MEDIAN |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | Nab-Paclitaxel With Gemcitabine | Complete Response | 0 | Participants | |
| Overall Response Rate | Nab-Paclitaxel With Gemcitabine | Partial Response | 9 | Participants | |
| Overall Response Rate | Nab-Paclitaxel With Gemcitabine | Stable Disease | 16 | Participants | |
| Overall Response Rate | Nab-Paclitaxel With Gemcitabine | Progressive Disease | 7 | Participants | |
| Progression-Free Survival | Nab-Paclitaxel With Gemcitabine | 2.9 | 95% Confidence Interval 2.4 to 3.6 | months | |
| Time to Progression | Nab-Paclitaxel With Gemcitabine | 2.9 | 95% Confidence Interval 2.4 to 3.8 | months | |
| Overall Survival | Nab-Paclitaxel With Gemcitabine | 9.3 | 95% Confidence Interval 5.2 to 12.4 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Nab-Paclitaxel With Gemcitabine | 32 | |
| Overall Study | COMPLETED | Nab-Paclitaxel With Gemcitabine | 2 | |
| Overall Study | NOT COMPLETED | Nab-Paclitaxel With Gemcitabine | 30 |
Source ClinicalTrials.gov
Adverse events141
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Nab-Paclitaxel With Gemcitabine | 19 | 32 | 59 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Nab-Paclitaxel With Gemcitabine | 1 | 32 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Nab-Paclitaxel With Gemcitabine | 2 | 32 | 2 |
| other | Chest pain - cardiac | Cardiac disorders | Nab-Paclitaxel With Gemcitabine | 1 | 32 | 1 |
| other | Heart failure | Cardiac disorders | Nab-Paclitaxel With Gemcitabine | 2 | 32 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Nab-Paclitaxel With Gemcitabine | 2 | 32 | 2 |
| other | Ear and labyrinth disorders - Other, specify | Ear and labyrinth disorders | Nab-Paclitaxel With Gemcitabine | 1 | 32 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Nab-Paclitaxel With Gemcitabine | 1 | 32 | 1 |
| other | Dry eye | Eye disorders | Nab-Paclitaxel With Gemcitabine | 1 | 32 | 2 |
| other | Eye disorders - Other, specify | Eye disorders | Nab-Paclitaxel With Gemcitabine | 1 | 32 | 1 |
1 to 10 of 141Source ClinicalTrials.gov
See all 141 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Nab-Paclitaxel With Gemcitabine | 31 | 32 |
| Total, other adverse events | Nab-Paclitaxel With Gemcitabine | 32 | 32 |
| Total, serious adverse events | Nab-Paclitaxel With Gemcitabine | 14 | 32 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39144826 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02769832
GET https://conductscience.org/api/trials/v1/NCT02769832/events?page=2